HeyJaredHead and Neck Oncology Journal Club
A weekly podcast breaking down the latest peer-reviewed research in head and neck surgery and oncology. Perfect for busy clinicians.
- Indexed episodes, last 90 days
- 6
- Latest publication
- Sep 22, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 4, 2026
Latest episodes
Does Postoperative Radiation Improve Survival in Salivary Gland Adenoid Cystic Carcinoma? (opens the original)
Read excerpt
After complete resection of a parotid or submandibular adenoid cystic carcinoma, does postoperative radiation help patients live longer? In this episode, we look at an updated National Cancer Database analysis from Memorial Sloan Kettering of 2,384 patients treated between 2004 and 2021. Postoperative radiation was associated with better 8-year overall survival: 76.9 percent against 70.3 percent, with an adjusted hazard ratio of 0.76. The benefit extended to early-stage and margin-negative disea
FDG PET/CT for Restaging and Distant Metastasis Detection in Recurrent Head and Neck Cancer (opens the original)
Read excerpt
Recurrent head and neck cancer forces one binary decision: salvageable, or systemic? The standard workup answers it with a chest CT. A 500-patient series from Tata Memorial suggests that's looking in the wrong place first, bone, not lung, was the commonest site of distant spread, and one patient in ten had metastases a neck and chest CT could not see. Full description Episode 22. Krishnakumar Thankappan reviews Prakash, Purandare and colleagues on FDG PET/CT for restaging recurrent head and neck
Superficial Parotidectomy: Why the Operation Is Built That Way (opens the original)
Read excerpt
Superficial parotidectomy is the removal of parotid tissue lateral to the plane of the facial nerve. That definition sets the terms of the operation: it is not a gland excision that happens to involve a nerve, but a nerve dissection from which the gland is delivered as a consequence. This episode is a companion to the step-by-step surgical video on the Head and Neck Cancers channel. The case is a pleomorphic adenoma of the lower pole of the right parotid. Rather than narrating the steps alone, t
Weekly or 3-Weekly Cisplatin? JCOG1008 at Five Years (opens the original)
Read excerpt
Most units moved to weekly cisplatin years before the randomised evidence caught up. JCOG1008 gave us the interim answer in 2022. This month brings the five-year data — and a number that is easy to misread. In this episode: Why the trial was designed as a noninferiority study, and what the 1.32 margin was chosen to preserve The five-year efficacy results across overall survival, relapse-free survival and local control Why "not worse" and "better" are different claims — and why the confidence int
Dabrafenib plus trametinib in BRAF V600E RAI-refractory thyroid cancer (opens the original)
Read excerpt
The first phase 3 trial of BRAF/MEK inhibition in radioactive iodine-refractory, BRAF V600E-positive differentiated thyroid cancer, and the results are decisive. In this global, double-blind trial (153 patients, 42 sites, 11 countries), previously treated patients who had progressed on one or two VEGFR-targeted therapies were randomised 2:1 to dabrafenib plus trametinib or placebo. Dabrafenib plus trametinib more than tripled median progression-free survival , 12.8 vs 3.7 months (HR 0.38, 95% CI
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.